NasdaqCM · Biotechnology

vTv Therapeutics (VTVT)

Stock, pipeline and biotech catalyst intelligence

Analyst view

Buy+61.9%

$53.83 average target

$33.26+0.17 (+0.5%)Latest market snapshot · Yahoo Finance

Market cap$131.5M

Cash$86.6M

Quarterly burn$11.4M

Pipeline assets5

Short float7.0%

Latest coverage

News & Press Releases

External sources

Aug 19, 2026

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire

Aug 6, 2026

vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswire

Aug 6, 2026

VTv Therapeutics: Q2 Earnings SnapshotAssociated Press

Company profile

About vTv Therapeutics

vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. vTv Therapeutics Inc. was incorporated in 2015 and is headquartered in High Point, North Carolina.

Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.

Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.